(MENAFN- GlobeNewsWire - Nasdaq) Opportunities center on targeted complement inhibitors, biologics, small molecules, RNA and gene therapies for rare diseases across ophthalmology, hematology and immunology.Dublin, Sept. 16, 2026 (GLOBE NEWSWIRE) -- "Next Generation Complement Therapeutics Market Report 2026" has been added to ResearchAndMarkets.com's offering.
Next-Generation Complement Therapeutics Market to Reach $15.29 Billion by 2030
The global next-generation complement therapeutics market is experiencing rapid expansion as demand rises for targeted treatments addressing rare, autoimmune, hematologic, ophthalmic and inflammatory disorders. The market is projected to grow from $7.38 billion in 2025 to $8.56 billion in 2026, representing a compound annual growth rate (CAGR) of 16%.
Historical market growth has been supported by the increasing prevalence of rare hematologic and autoimmune diseases, regulatory approvals for first-generation complement inhibitors and expanding clinical research in hematology and ophthalmology. The limited availability of complement-targeting treatments and continued reliance on conventional immunosuppressive therapies have also created significant demand for more precise and effective therapeutic options.
The next-generation complement therapeutics market is forecast to reach $15.29 billion by 2030, advancing at a CAGR of 15.6% from 2026. Key growth drivers include the development of novel C3, C5, factor B and factor D inhibitors, increased adoption of combination therapies and greater investment in rare disease research. Rising healthcare expenditure on advanced immune therapies and progress in gene- and RNA-based medicines are also expected to support market expansion.
Major next-generation complement therapeutics market trends include growing adoption of targeted therapies for rare diseases, increased use of biologics and small-molecule complement inhibitors, and continued development of both monotherapy and adjunctive therapy approaches. Applications are expanding across ophthalmology, hematology, neurology, immunology and rheumatology, while personalized medicine and gene-based therapeutic strategies are creating new opportunities for drug developers.
The rising prevalence of chronic diseases is expected to strengthen demand for next-generation complement therapeutics. Sedentary lifestyles, reduced physical activity and associated metabolic disruption are contributing to higher long-term health risks worldwide. By selectively modulating complement pathway activity, these therapies may help reduce inflammation and limit immune-mediated tissue damage in relevant complement-driven conditions.
For example, data published by the UK National Health Service in June 2024 showed that 3,615,330 people registered with a general practitioner had been diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023. This represented an 18% increase from 3,065,825 cases in 2022, illustrating the growing burden of chronic health conditions and the broader need for advanced therapeutic research.
Innovation remains a central focus within the next-generation complement therapeutics industry. Drug developers are advancing targeted complement inhibitors intended to improve treatment outcomes for severe and rare complement-mediated diseases. Current research priorities include more selective pathway inhibition, convenient administration options, improved patient adherence and favorable safety profiles compared with conventional systemic treatments.
Strategic partnerships are also accelerating complement-targeted drug discovery and development. In March 2023, China-based healthcare technology company Pharmaron Inc. partnered with Complement Therapeutics Inc. to support the development of new complement-targeted therapies. The collaboration combines integrated preclinical and clinical research capabilities with specialized drug discovery expertise. It is intended to improve development efficiency, strengthen data quality and shorten timelines for treatments addressing rare and autoimmune diseases.
North America was the largest region in the next-generation complement therapeutics market in 2025, supported by established biopharmaceutical research infrastructure, investment in rare disease therapies and strong clinical development activity. Asia-Pacific is expected to be the fastest-growing region during the forecast period. The market analysis covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy and Spain.
Markets Covered:
1) By Type Of Therapy: Monotherapy; Adjunctive Therapy
2) By Molecule Type: Biologic; Small Molecule
3) By Route Of Administration: Intravenous; Oral; Intravitreal; Subcutaneous
4) By Indication: Paroxysmal Nocturnal Hemoglobinuria; Geographic Atrophy (GA) Secondary To Age-Related Macular Degeneration; Generalized Myasthenia Gravis; Atypical Hemolytic Uremic Syndrome; Other Indications
5) By Therapeutic Area: Hematology; Ophthalmology; Neurology; Immunology Or Rheumatology; Other Therapeutic Areas
Subsegments:
1) By Monotherapy: C3 Inhibitors; C5 Inhibitors; Factor D Inhibitors; Factor B Inhibitors; C1 Inhibitors; MASP-2 Inhibitors
2) By Adjunctive Therapy: Combination With Immunosuppressants; Combination With Steroids; Combination With Plasma Exchange; Combination With Biologics; Combination With Chemotherapeutics; Combination With Anticoagulants
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment